Abstract: A semiconductor device includes a semiconductor element, a wiring member, a sintered member between a first main electrode of the semiconductor element and the wiring member, and a sealing body. The wiring member includes a base material, a metal film on a face of the base material, and an uneven oxide film. The uneven oxide film includes a thick film portion and a thin film portion. An opposing face of the wiring member opposing the semiconductor element includes a mounting portion to which the first main electrode is bonded, an outer peripheral portion formed with the thick film portion and surrounding the semiconductor element, and an intermediate portion formed with the thin film portion between the mounting portion and the outer peripheral portion. The sintered member overlaps with the mounting portion and the intermediate portion in the plan view, and is in contact with the thin film portion.

Abstract: In a pharmaceutical composition for oral administration comprising 6-(4,4-dimethylcyclohexyl)-4-[(1,1-dioxo-1?6-thiomorpholin-4-yl)methyl]-2-methylthieno[2,3-d]pyrimidine or a pharmaceutically acceptable salt thereof, a stable pharmaceutical composition for oral administration with rapid drug dissolution properties is provided. The pharmaceutical composition for oral administration contains a water-swellable substance, which is a polymer compound obtained by condensation polymerization of ?-glucose, a polymer compound obtained by condensation polymerization of ?-glucose, or a polymer compound having a pyrrolidone functional group.

Abstract: A mobile carriage includes a traveling part, a wheel, a bed, a displacement conversion part, and an elastic member. The wheel is provided on the traveling part. The bed is supported by the traveling part to be movable in a traveling direction of the traveling part. The displacement conversion part displaces the wheel relative to the traveling part in accordance with displacement of the bed relative to the traveling part. The elastic member applies a force to return the bed having moved relative to the traveling part to an initial position before the movement. The displacement conversion part displaces the wheel relative to the traveling part in a direction of inertial force acting on the bed.

Abstract: Disclosed is a test instrument for measuring an analyte in a liquid sample by a noble metal colloid aggregation measurement method. The test instrument involves a reaction chamber in which at least the liquid sample is to be reacted with a reagent, wherein the reagent is adhered on at least a part of a surface constituting the reaction chamber in a dried state, and the reagent enables the measurement of the analyte by a noble metal colloid aggregation measurement method.

Abstract: Provided is a pharmaceutical composition for oral administration in which the solubility and/or dissolution properties of enzalutamide are improved and supersaturation is maintained. Also provided is a pharmaceutical composition for oral administration in which the oral absorbability of enzalutamide is improved. The pharmaceutical composition for oral administration comprises enzalutamide and polyvinyl alcohol.

Abstract: Disclosed is a pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, which is a compound having pH-dependent solubility, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. In the pharmaceutical composition for oral administration, the solubility and absorbability of the drug are improved.

Abstract: Disclosed is a pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, which is a compound having pH-dependent solubility, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. In the pharmaceutical composition for oral administration, the solubility and absorbability of the drug are improved.

Abstract: Disclosed is a pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, which is a compound having pH-dependent solubility, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. In the pharmaceutical composition for oral administration, the solubility and absorbability of the drug are improved.

Abstract: An autoantibody against Ku86 can be measured by reacting the autoantibody contained in a sample with a Ku86 antigen (which serves as a reagent) to produce an immune complex of the autoantibody and the Ku86 antigen and measuring the immune complex using a labeled anti-human immunoglobulin antibody. The measurement of the autoantibody enables the determination of primary hepatocellular carcinoma.

Abstract: Pentameric CRP is produced at a high efficiency by transferring DNA, which encodes monomeric CRP, into a silkworm to thereby construct a transgenic silkworm and then collecting and purifying pentameric CRP that is produced by the transgenic silkworm constructed above.

Abstract: Disclosed is an immunoassay method whereby a 5.9 kDa peptide which results from the degradation of the ?-E chain and ? chain of human fibrinogens and which is used as a peptide marker for diagnosing hepatic disease can be specifically assayed in a biological sample containing contaminating peptides by bringing antibodies that recognize the N terminal of said peptide marker and antibodies that recognize the C terminal of said peptide marker into contact with said peptide marker, forming immune complexes of said peptide marker and the two antibodies, and immunoassaying the obtained immune complexes.

Abstract: Pentameric CRP is produced at a high efficiency by transferring DNA, which encodes monomeric CRP, into a silkworm to thereby construct a transgenic silkworm and then collecting and purifying pentameric CRP that is produced by the transgenic silkworm constructed above.

Abstract: In the case of assaying the level of complex AB in a sample which likely contains the complex AB composed of substance A with another substance B, the complex is assayed by the competitive homogeneous assay method with the use of reagents including a reagent containing partner C specifically binding to substance A, a reagent containing partner D specifically binding to substance B, a reagent containing fine particles carrying substance A or an analog thereof and substance B or an analog thereof, and a reagent containing partner C specifically binding to substance A and partner D specifically binding to substance B. Thus, the complex in the sample can be easily assayed. The above method is applicable to general-purpose biochemical automatic analyzers.

Abstract: Pentameric CRP is produced at a high efficiency by transferring DNA, which encodes monomeric CRP, into a silkworm to thereby construct a transgenic silkworm and then collecting and purifying pentameric CRP that is produced by the transgenic silkworm constructed above.

Abstract: Pentameric CRP is produced at a high efficiency by transferring DNA, which encodes monomeric CRP, into a silkworm to thereby construct a transgenic silkworm and then collecting and purifying pentameric CRP that is produced by the transgenic silkworm constructed above.

Abstract: In measuring phosphoric acid by the use of an enzyme cycling system using a dehydrogenase together with a thio-NADP, a thio-NAD, a reduced thio-NADP or a reduced thio-NAD as a coenzyme, phosphoric acid is measurable in a wide concentration range from a low concentration to a high concentration by measuring phosphoric acid after previous removal of free phosphoric acid in reagent components for the measurement.

Abstract: An optical information recording medium (1) includes on a substrate (50), a ROM layer (20), a RE layer (40), an intermediate layer (30) separating the ROM layer (20) and the RE layer (40), and a light transmitting layer (10) provided farthest from the substrate (50). The RE layer (40) is an information recording layer provided most farthest from the light transmitting layer (10), and is a recording layer of BCA recorded in a format easily determinable as compared to an information recording format used in the ROM layer (20), and antifouling property of a surface of the light transmitting layer (10) is set based on the RE layer (40). This makes it easy for the recording and reproducing apparatus to confirm a disc type, allows for sharing one recording and reproducing apparatus with other types of optical discs, and simplifies the disc production.

Abstract: Disclosed is a test instrument for measuring an analyte in a liquid sample by a noble metal colloid aggregation measurement method. The test instrument involves a reaction chamber in which at least the liquid sample is to be reacted with a reagent, wherein the reagent is adhered on at least a part of a surface constituting the reaction chamber in a dried state, and the reagent enables the measurement of the analyte by a noble metal colloid aggregation measurement method.

Abstract: A reaginic antibody of Ku86 and a substance capable of binding with the autoantibody of Ku86 are acted on a complex of Ku86 and the autoantibody thereof in a subject. Said complex can be measured by measuring the obtained immune complex of the aforementioned complex, reaginic antibody, and substance capable of binding with the autoantibody of Ku86. As a consequence, it is possible to determine whether the cancer is a primary hepatoma, colon cancer, stomach cancer, pancreatic cancer, breast cancer, lung cancer, or an esophageal cancer.

Abstract: An autoantibody against Ku86 can be measured by reacting the autoantibody contained in a sample with a Ku86 antigen (which serves as a reagent) to produce an immune complex of the autoantibody and the Ku86 antigen and measuring the immune complex using a labeled anti-human immunoglobulin antibody. The measurement of the autoantibody enables the determination of primary hepatocellular carcinoma.